Rating scales in schizophrenia: A review of their usefulness for assessing atypical antipsychotics

CNS Drugs

Volumn 14, Issue 1, 2000, Pages 23-32

  Lader, Malcolm ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE; ZOTEPINE;

CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG EFFICACY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; META ANALYSIS; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA;

EID: 0033865311     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200014010-00003     Document Type: Review

References (55)

1. 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
2. 2. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia. London: European Medicines Evaluation Agency (EMEA), 1998 Feb 26
3. 3. Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical'? Conserving the definition. CNS Drugs 1997; 7: 341-6
4. 4. Coukell AJ, Spencer CM, Benfield P. Amisulpiride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996; 6: 237-56
5. 5. Fulton B, Goa, KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997; 53: 281-96
6. 6. Editorial. Seroquel: a putative atypical antipsychotic drug with serotonin-and dopamine-receptor antagonist properties. J Clin Psychiatry 1995; 56: 438-45
7. 7. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999; 35: 51-68
8. 8. Tandon R, Harrigan E, Zorn SH. Ziprasidone: a novel antipsychotic with unique pharmacology and therapeutic potential. J Serotonin Res 1997; 4: 159-77
9. 9. Davis R, Markham A. Ziprasidone. CNS Drugs 1997; 8: 153-62
10. 10. Möller H-J, van Praag HM, Aufdembrinke B, et al. Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia. Psychopharmacology 1994; 115: 221-8
11. 11. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799-812
12. 12. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-76
13. 13. Singh MM, Kay SR. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: theoretical implications for potency differences among neuroleptics. Psychopharmacologia 1975; 43: 103-13
14. 14. Bell M, Milstein R, Beam-Goulet J, et al. The Positive and Negative Syndrome Scale and the Brief Psychiatric Rating Scale. Reliability, comparability and predictive validity. J Nerv Ment Dis 1992; 180: 723-8
15. 15. Andreasen N. Scale for the assessment of negative symptoms (SANS). Br J Psychiatry 1989; 155 Suppl. 7: 53-8
16. 16. Andreasen N. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982; 39: 784-8
17. 17. Czobor P, Bitter I, Volavka J. Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Res 1991; 36: 129-39
18. 18. National Institute of Mental Health. Clinical global impressions In: Guy W, editor. ECDEU assessment manual for psychopharmacology. Rev ed. Rockville (MD): Department of Health, Education and Welfare (DHEW), 1976: 157-69
19. 19. Müller N, Möller H-J. Amisulprid in der Therapie chronisch schizophrener Patienten. Ergebnisse klinischer Studien. Psychopharmakotherapie 1999; 6 Suppl. 9: 15-9
20. 20. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996; 124: 159-67
21. 21. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14: 111-23
22. 22. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998; 18: 41-9
23. 23. Borison RL, Arvanitis LA, Miller BG, et al. ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 1996; 16: 158-69
24. 24. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-57
25. 25. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28: 213-8
26. 26. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13: 25-40
27. 27. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35
28. 28. Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120mg/day in the acute exacerbation of schizophrenia and schizoaffective disorders: a 4-week placebo-controlled trial. Psychopharmacology 1988; 140: 173-84
29. 29. Peuskens J, Bech P, Möller HJ, et al. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999; 80: 107-17
30. 30. Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacology 1999; 14: 1-10
31. 31. Delcker A, Schoon ML, Oczkowski B, et al. Amisulpride versus haloperidol in treatment of schizophrenic patients: results of a double-blind study. Pharmacopsychiatry 1990; 23: 125-30
32. 32. Möller HJ, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparsion with haloperidol. Psychopharmacology 1997; 132: 396-401
33. 33. Wetzel H, Gründer G, Hillert A, al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. Psychopharmacology 1998; 137: 223-32
34. 34. Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125-37
35. 35. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998; 155: 914-20
36. 36. Glazer WM. Olanzapine and the new generation of antipsychotic agents: patterns of use. J Clin Psychiatry 1997; 58 Suppl. 10: 18-21
37. 37. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154: 457-65
38. 38. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18
39. 39. Tran PV, Tollefson GD, Sanger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Br J Psychiatry 1999; 174: 15-22
40. 40. Arvanitis LA, Miller BG, Seroquel Trial 13 Study Group. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-46
41. 41. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 1997; 96: 265-73
42. 42. Claus A, Bollen J, de Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenia inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305
43. 43. Bondolfi G, Dufour H, Patris M et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155: 499-504
44. 44. Breier AF, Malhotra AK, Su T-P, et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 1999; 156: 294-8
45. 45. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993; 88: 395-402
46. 46. Huttunen MO, Piepponen T, Rantanen H, et al. Risperidone versus zuclopenthixol in the treatment of actue schizophrenic episodes: a double-blind parallel group trial. Acta Psychiatr Scand 1995; 91: 271-7
47. 47. Lindenmayer J-P, Iskander A, Park M, et al. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenia patients: a prospective study. J Clin Psychiatry 1998; 59: 521-7
48. 48. Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993; 34: 179-90
49. 49. Möller H-J, Bäuml J, Ferrero F, et al. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. Eur Arch Psychiatry Clin Neurosci 1997; 247: 291-6
50. 50. Peusken J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166: 712-26
51. 51. Daniel DG, Wozniak P, Mack RJ, et al. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. Psychopharmacology Bull 1998; 34: 61-9
52. 52. Fleischhacker WW, Barnas C, Stuppäck CH, et al. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacology Bull 1989; 25: 97-100
53. 53. Meyer-Lindenberg A, Gruppe H, Bauer U, et al. Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 1997; 30: 35-42
54. 54. Petit M, Raniwalla J, Tweed J, et al. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial. Psychopharmacology Bull 1996; 32: 81-7
55. 55. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1988; 45: 789-96